{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:19:27Z","timestamp":1761664767915,"version":"build-2065373602"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Patolog\u00eda"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.patol.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T07:24:58Z","timestamp":1661585098000},"page":"45-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology"],"prefix":"10.1016","volume":"56","author":[{"given":"Jos\u00e9 Manuel Trigo","family":"P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Garc\u00eda-Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Garc\u00eda-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Gom\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricard","family":"Mesia-Nin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ruiz-Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainara","family":"Soria-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Bra\u00f1a-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Alberola-Ferranti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.patol.2022.06.003_bib0445","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.patol.2022.06.003_bib0450","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0455","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ijrobp.2008.04.006","article-title":"Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)","volume":"71","author":"Garden","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.patol.2022.06.003_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0360-3016(99)00558-1","article-title":"Toxicity in head and neck cancer: a review of trends and issues","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiaton Oncol Biol Phys"},{"key":"10.1016\/j.patol.2022.06.003_bib0465","doi-asserted-by":"crossref","DOI":"10.3390\/v13071326","article-title":"A contemporary systematic review on repartition of HPV-positivity in oropharyngeal cancer worldwide","volume":"13","author":"Carlander","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.patol.2022.06.003_bib0470","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0475","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.patol.2022.06.003_bib0480","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.patol.2022.06.003_bib0485","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl. 5","key":"10.1016\/j.patol.2022.06.003_bib0490","first-page":"S583","article-title":"Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer","volume":"32","author":"Brose","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0495","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1158\/1535-7163.MCT-19-0958","article-title":"Tipifarnib as a precision therapy for HRAS-mutant head and neck squamous cell carcinomas","volume":"19","author":"Gilardi","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.patol.2022.06.003_bib0500","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/annonc\/mdx304","article-title":"Human papillomavirus-related oropharyngeal cancer","volume":"28","author":"Taberna","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0505","first-page":"8","article-title":"Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma","volume":"2","author":"Faraji","year":"2017","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.patol.2022.06.003_bib0510","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdt574","article-title":"Impact of tumor HPV status on outcome in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial","volume":"25","author":"Vermorken","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0515","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1200\/JCO.2014.58.6412","article-title":"Refining American Joint Committee on Cancer\/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas","volume":"33","author":"Huang","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0520","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(15)00560-4","article-title":"Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study","volume":"17","author":"O'Sullivan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0525","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.oraloncology.2016.09.004","article-title":"Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx","volume":"62","author":"Haughey","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0530","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5858\/arpa.2017-0286-CP","article-title":"Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists","volume":"142","author":"Lewis","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0535","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/hed.25591","article-title":"HPV as a marker for molecular characterization in head and neck oncology: looking for a standardization of clinical use and of detection method(s) in clinical practice","volume":"41","author":"Bussu","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.patol.2022.06.003_bib0540","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.18.00684","article-title":"Human papillomavirus testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the College of American Pathologists Guideline","volume":"36","author":"Fakhry","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0545","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000496158","article-title":"Current status of p16 immunohistochemistry and HPV testing in fine needle aspiration specimens of the head and neck","volume":"64","author":"Jalaly","year":"2020","journal-title":"Acta Cytol"},{"issue":"Suppl. 4","key":"10.1016\/j.patol.2022.06.003_bib0550","first-page":"S599","article-title":"Performance of dual p16 and HPV testing for determining prognosis in cancer of the oropharynx, the EPIC-OPC study","volume":"31","author":"Mehanna","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0555","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1158\/1078-0432.CCR-11-0388","article-title":"Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination","volume":"17","author":"Schache","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.patol.2022.06.003_bib0560","doi-asserted-by":"crossref","first-page":"104652","DOI":"10.1016\/j.oraloncology.2020.104652","article-title":"Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: current state and future directions","volume":"105","author":"Bigelow","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0565","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.patol.2022.06.003_bib0570","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.patol.2022.06.003_bib0575","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0580","unstructured":"EMA. Pembrolizumab European Assessment Report EMA\/CHMP\/591139\/2019. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf."},{"key":"10.1016\/j.patol.2022.06.003_bib0585","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0590","first-page":"21","article-title":"SEOM clinical guidelines for the treatment of head and neck cancer (2020)","volume":"23","author":"Mesia","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0595","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.patol.2022.06.003_bib0600","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0605","article-title":"Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study","author":"Cerbelli","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.patol.2022.06.003_bib0610","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/cancers13020292","article-title":"PD-L1 testing and squamous cell carcinoma of the head and neck: a multicenter study on the diagnostic reproducibility of different protocols","volume":"13","author":"Crosta","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.patol.2022.06.003_bib0615","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"de Ruiter","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.patol.2022.06.003_bib0620","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.3747\/co.25.4031","article-title":"Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective","volume":"25","author":"Ionescu","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0625","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","article-title":"\u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy","volume":"33","author":"Torlakovic","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.patol.2022.06.003_bib0630","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.patol.2022.06.003_bib0635","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.patol.2022.06.003_bib0640","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-Barr virus infection and nasopharyngeal carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.patol.2022.06.003_bib0645","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1055-9965.EPI-13-1262","article-title":"Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan","volume":"23","author":"Coghill","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.patol.2022.06.003_bib0650","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein\u2013Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0655","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.oraloncology.2018.11.020","article-title":"Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck","volume":"88","author":"Golusinski","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0660","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archoto.2009.145","article-title":"Metastatic carcinoma of the neck of unknown primary origin: evolution and efficacy of the modern workup","volume":"135","author":"Waltonen","year":"2009","journal-title":"Arch Otolaryngol \u2013 Head Neck Surg"},{"key":"10.1016\/j.patol.2022.06.003_bib0665","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.semdp.2014.12.002","article-title":"Cytologic evaluation of cervical lymph node metastases from cancers of unknown primary origin","volume":"32","author":"Pusztaszeri","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.patol.2022.06.003_bib0670","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1200\/JCO.20.00275","article-title":"Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline","volume":"38","author":"Maghami","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0675","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.oraloncology.2012.05.022","article-title":"HPV status in patients with head and neck of carcinoma of unknown primary site: HPV, tobacco smoking, and outcome","volume":"48","author":"Tribius","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0680","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/jop.12741","article-title":"Androgen receptor in salivary gland carcinoma: a review of an old marker as a possible new target","volume":"47","author":"Yeoh","year":"2018","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0685","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers9020017","article-title":"Androgen receptor signaling in salivary gland cancer","volume":"9","author":"Dalin","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.patol.2022.06.003_bib0690","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1002\/cam4.2602","article-title":"Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling","volume":"8","author":"Gargano","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0695","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.humpath.2019.08.007","article-title":"Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance","volume":"93","author":"Xu","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.patol.2022.06.003_bib0700","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0705","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"110","author":"van Boxtel","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.patol.2022.06.003_bib0710","doi-asserted-by":"crossref","first-page":"693394","DOI":"10.3389\/fonc.2021.693394","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0715","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0720","first-page":"34","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.patol.2022.06.003_bib0725","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2021.39.15_suppl.3004","article-title":"MyPathway HER2 basket study: pertuzumab (P)+trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors","volume":"39","author":"Meric-Bernstam","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.patol.2022.06.003_bib0730","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0735","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/curroncol28010053","article-title":"Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults","volume":"28","author":"Bebb","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0740","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s12094-021-02558-0","article-title":"Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours","volume":"23","author":"Garrido","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0745","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.patol.2022.06.003_bib0750","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0755","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0760","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4161\/sgtp.1.1.12178","article-title":"Ras history: the saga continues","volume":"1","author":"Cox","year":"2010","journal-title":"Small GTPases"},{"key":"10.1016\/j.patol.2022.06.003_bib0765","first-page":"82","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.patol.2022.06.003_bib0770","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0775","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.patol.2022.06.003_bib0780","doi-asserted-by":"crossref","first-page":"24014","DOI":"10.1038\/srep24014","article-title":"Somatic mutations and genetic variants of NOTCH1 in head and neck squamous cell carcinoma occurrence and development","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.patol.2022.06.003_bib0785","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-18-3276","article-title":"PDK1 mediates NOTCH1-mutated head and neck squamous carcinoma vulnerability to therapeutic PI3K\/mTOR inhibition","volume":"25","author":"Sambandam","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.patol.2022.06.003_bib0790","doi-asserted-by":"crossref","first-page":"113729","DOI":"10.1016\/j.bcp.2019.113729","article-title":"PI3K\/AKT\/mTOR signaling as a molecular target in head and neck cancer","volume":"172","author":"Marquard","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.patol.2022.06.003_bib0795","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/hed.25910","article-title":"A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer","volume":"41","author":"Brisson","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.patol.2022.06.003_bib0800","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"18","author":"Souli\u00e8res","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0805","doi-asserted-by":"crossref","first-page":"e0245715;","DOI":"10.1371\/journal.pone.0245715","article-title":"PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy","volume":"16","author":"Chuang","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.patol.2022.06.003_bib0810","doi-asserted-by":"crossref","first-page":"104753","DOI":"10.1016\/j.oraloncology.2020.104753","article-title":"trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck","volume":"108","author":"Day","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0815","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijrobp.2019.09.050","article-title":"A phase 1b study of cetuximab and BYL719 (Alpelisib) concurrent with intensity modulated radiation therapy in stage III\u2013IVB head and neck squamous cell carcinoma","volume":"106","author":"Dunn","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.patol.2022.06.003_bib0820","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"21","author":"Linnemann","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0825","doi-asserted-by":"crossref","first-page":"e000442","DOI":"10.1136\/esmoopen-2018-000442","article-title":"Implementing TMB measurement in clinical practice: considerations on assay requirements","volume":"4","author":"B\u00fcttner","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.patol.2022.06.003_bib0830","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0835","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98811","article-title":"Frameshift events predict anti-PD-1\/L1 response in head and neck cancer","volume":"3","author":"Hanna","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.patol.2022.06.003_bib0840","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.patol.2022.06.003_bib0845","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0850","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.patol.2022.06.003_bib0855","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hed.23100","article-title":"Lessons learned from next-generation sequencing in head and neck cancer","volume":"35","author":"Loyo","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/j.patol.2022.06.003_bib0860","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2022.06.003_bib0865","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/PAS.0000000000000980","article-title":"The role of molecular testing in the differential diagnosis of salivary gland carcinomas","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.patol.2022.06.003_bib0870","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2022.06.003_bib0875","first-page":"4","article-title":"Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the association for molecular pathology and the College of American Pathologists","volume":"20","author":"Roy","year":"2018","journal-title":"JMD"},{"key":"10.1016\/j.patol.2022.06.003_bib0880","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1158\/1078-0432.CCR-15-2314","article-title":"Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma","volume":"22","author":"Chau","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Revista Espa\u00f1ola de Patolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699885522000459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699885522000459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:06:51Z","timestamp":1761664011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699885522000459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1699885522000459"],"URL":"https:\/\/doi.org\/10.1016\/j.patol.2022.06.003","relation":{},"ISSN":["1699-8855"],"issn-type":[{"type":"print","value":"1699-8855"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Patolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.patol.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Anatom\u00eda Patol\u00f3gica.","name":"copyright","label":"Copyright"}]}}